ArticleCureus2024
Pericardial Effusion as a Presentation of Lymphangioleiomyomatosis.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphangioleiomyomatosis (LAM) is a rare, systemic neoplastic disease that primarily affects women of childbearing age. The disease can arise sporadically or in association with tuberous sclerosis. It is characterized by the proliferation of abnormal smooth muscle-like cells, leading to cystic lung destruction, accumulation of chylous fluid, and development of abdominal tumors. The main clinical presentations are pneumothorax and progressive dyspnea on exertion. In some patients, the onset of symptoms occurs while on estrogen replacement therapy or during pregnancy. Since most patients present with common lung symptoms, such as fatigue and dyspnea, LAM is often the last diagnosis to consider. Worsening symptoms with the menstrual cycle can help raise this suspicion. This report describes a case of LAM in which the lack of awareness about this rare disease led to a significant diagnostic delay. A 34-year-old Caucasian woman presented with symptoms of dyspnea and fatigue that began during her second pregnancy, which were initially misinterpreted as obstructive lung disease for three years. As the disease evolved, the development of a pericardial effusion, a rare manifestation of the disease, led to the need to perform computed tomography, revealing multiple thin-walled intrapulmonary cysts with diffuse distribution suggestive of LAM, mediastinal lymphadenopathy, and lymphangioma. Serum vascular endothelial growth factor A levels were normal, and spirometry testing revealed severe airflow obstruction. Based on clinical and imaging findings, a diagnosis of LAM was made. With this article, we intend to raise awareness for the manifestations of this disease and its relation to hormonal changes and review treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.